AP2001002072A0 - Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride - Google Patents

Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride

Info

Publication number
AP2001002072A0
AP2001002072A0 AP2001002072A AP2001002072A AP2001002072A0 AP 2001002072 A0 AP2001002072 A0 AP 2001002072A0 AP 2001002072 A AP2001002072 A AP 2001002072A AP 2001002072 A AP2001002072 A AP 2001002072A AP 2001002072 A0 AP2001002072 A0 AP 2001002072A0
Authority
AP
ARIPO
Prior art keywords
preparation
paroxetine hydrochloride
anhydrate form
crystalline anhydrate
crystalline
Prior art date
Application number
AP2001002072A
Other languages
English (en)
Original Assignee
Smithkline Becham P L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817196.0A external-priority patent/GB9817196D0/en
Priority claimed from GBGB9828777.4A external-priority patent/GB9828777D0/en
Application filed by Smithkline Becham P L C filed Critical Smithkline Becham P L C
Publication of AP2001002072A0 publication Critical patent/AP2001002072A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2001002072A 1998-08-07 1999-08-06 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride AP2001002072A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9817196.0A GB9817196D0 (en) 1998-08-07 1998-08-07 Novel process
GBGB9828777.4A GB9828777D0 (en) 1998-12-29 1998-12-29 Novel compounds
PCT/GB1999/002592 WO2000008017A1 (en) 1998-08-07 1999-08-06 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride

Publications (1)

Publication Number Publication Date
AP2001002072A0 true AP2001002072A0 (en) 2001-03-31

Family

ID=26314179

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2001002072A AP2001002072A0 (en) 1998-08-07 1999-08-06 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
APAP/P/2001/002072A AP0102072A0 (en) 1998-08-07 1999-08-06 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002072A AP0102072A0 (en) 1998-08-07 1999-08-06 Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride.

Country Status (24)

Country Link
EP (2) EP1321465A3 (ja)
JP (1) JP2002522434A (ja)
KR (1) KR20010072323A (ja)
CN (1) CN1321155A (ja)
AP (2) AP2001002072A0 (ja)
AT (1) ATE239016T1 (ja)
AU (1) AU5428999A (ja)
BG (1) BG105310A (ja)
BR (1) BR9912858A (ja)
CA (1) CA2339857A1 (ja)
DE (1) DE69907467T2 (ja)
DK (1) DK1100796T3 (ja)
EA (1) EA200100221A1 (ja)
ES (1) ES2198940T3 (ja)
HK (1) HK1038230A1 (ja)
HU (1) HUP0105466A3 (ja)
ID (1) ID27914A (ja)
IL (1) IL141286A0 (ja)
NO (1) NO20010629L (ja)
PL (1) PL345885A1 (ja)
PT (1) PT1100796E (ja)
SK (1) SK1972001A3 (ja)
TR (1) TR200100444T2 (ja)
WO (1) WO2000008017A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394160A1 (en) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Process for preparing crystalline paroxetin hydrochloride
JP3796351B2 (ja) 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
JP2005538031A (ja) * 2000-11-17 2005-12-15 イーライ・リリー・アンド・カンパニー ラクタム化合物
US8697094B2 (en) * 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
AP9901604A0 (en) * 1997-01-15 1999-09-30 Smithkline Beecham Plc Paroxetine compositions.
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法

Also Published As

Publication number Publication date
DK1100796T3 (da) 2003-08-25
ES2198940T3 (es) 2004-02-01
DE69907467T2 (de) 2004-03-11
PT1100796E (pt) 2003-09-30
EP1100796B1 (en) 2003-05-02
EP1321465A3 (en) 2003-09-03
ID27914A (id) 2001-05-03
IL141286A0 (en) 2002-03-10
PL345885A1 (en) 2002-01-14
CN1321155A (zh) 2001-11-07
AP0102072A0 (en) 2001-02-06
SK1972001A3 (en) 2001-08-06
CA2339857A1 (en) 2000-02-17
TR200100444T2 (tr) 2001-07-23
JP2002522434A (ja) 2002-07-23
HUP0105466A3 (en) 2002-11-28
EP1100796A1 (en) 2001-05-23
DE69907467D1 (de) 2003-06-05
BG105310A (en) 2001-12-29
EA200100221A1 (ru) 2001-08-27
ATE239016T1 (de) 2003-05-15
WO2000008017A1 (en) 2000-02-17
HUP0105466A2 (hu) 2002-05-29
AU5428999A (en) 2000-02-28
NO20010629L (no) 2001-03-20
KR20010072323A (ko) 2001-07-31
NO20010629D0 (no) 2001-02-06
BR9912858A (pt) 2001-11-20
HK1038230A1 (en) 2002-03-08
EP1321465A2 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
SG43787A1 (en) Novel paroxetine hydrochloride anhydrate
HK1029529A1 (en) Novel process for manufacturing paroxetine solid dispersions
HK1065803A1 (en) Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
PL348858A1 (en) Method for producing l-phenylephrine hydrochloride
AU1987400A (en) Process for preparation of paroxetine maleate
AP2001002072A0 (en) Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
IL137684A0 (en) Salts of paroxetine
EP1185266A4 (en) AMORPHOUS FORM OF FEXOFENADINE CHLORYDRATE
PL345365A1 (en) Salts of paroxetine
HUP0004503A3 (en) Process for the preparation of paroxetine hydrochloride
AU1397800A (en) Method of producing paroxetine hydrochloride
HUP9900761A3 (en) A process for the preparation of 4-(desdimethyl-amino)-tetracyclines
AU1398500A (en) Process for the production of paroxetine hydrochloride propan-2-ol solvate
AU6481799A (en) Process for the preparation of paroxetine hydrochloride
AU1396400A (en) Process for the preparation of paroxetine hydrochloride
PL342931A1 (en) Crystalline form of paroxetine
EP1242362A4 (en) METHOD FOR PRODUCING FLUOXETINE HYDROCHLORIDE
AU6580800A (en) Process for the preparation of paroxetine hydrochloride
AU1396600A (en) Process for the preparation of paroxetine hydrochloride
LT96007A (en) Paroxetine hydrochloride anhydrate and process for preparing thereof
AU7025800A (en) Process for the preparation of 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine
AU1398300A (en) Amine salts of paroxetine
AU740561C (en) Paroxetine hydrochloride anhydrate
AU5550900A (en) Process for the production of paroxetine hydrochloride
IL140632A0 (en) A novel process for the preparation of paroxetine and novel intermediates thereof